Introduction
Leukemia-initiating cells, also termed leukemic stem cells (LSCs), are implicated in sustaining the malignancy and thus a poor treatment outcome. 1 Relapse may occur because of the resistance of quiescent LSCs to cell cycle-dependent cytotoxic chemotherapies. Consequently, specific targeting of LSCs has emerged as a novel therapeutic goal. 2 Natural killer (NK) cells are the innate immunity lymphocytes designated to recognize and kill malignant cells. 3 This property has been clinically verified in acute myeloid leukemia (AML) by graft-versus-leukemia effect improving the outcome of recipients of stem cells from haploidentical donors. 4, 5 The alloreactivity of NK cells is based on the absence of inhibitory killer immunoglobulin-like receptors (KIRs) engagement with human leukocyte antigen (HLA) class I molecules, and is triggered by cognate recognition of cell surface ligands by activating NK cell receptors. 6 NKG2D ligands (NKG2D-L) serve as tumor-specific antigens initiating NKG2D receptordependent activation of NK cells. 7, 8 While numerous studies have characterized the cytolytic potential of human NK cells against leukemic blasts, 9-12 their ability to target LSCs has not been examined. Although the precise phenotypic identity of human LSCs remains elusive, AML-initiating LSCs were shown to reside within the CD34 +
CD38
-population, the phenotype of which corresponds to a healthy bone marrow population containing the hematopoietic stem cells (HSCs). [13] [14] [15] Here we demonstrate that AML-CD34 +
-LSCs are efficiently recognized and destroyed by single KIR + NK cells with predicted mismatch with respect to HLA class I specificity of the AML patient. This study provides arguments for exploiting immunotherapy with alloreactive NK cells to target LSCs.
Design and Methods

Patients and healthy controls
Peripheral blood (PB) from AML patients (n=8) and normal bone marrow (N-BM) or normal G-CSF mobilized PB (N-mPB) from healthy donors (n=8) were obtained with informed consent, in agreement with the guidelines of the Ethical 
Flow cytometry (FACS)
Fluorochrome-conjugated monoclonal antibodies (mAbs) against human CD45, CD34, CD38, and control IgG1 (BD Biosciences, San Jose, CA) were used. Unconjugated mAbs against ULBP1 (M295), ULBP2 (M311), ULBP3 (M551) (D Cosman, Amgen, WA, USA), and MICA/B (BD Biosciences), all at 10 µg/mL, were revealed with goat α-mouse IgG-FITC (Jackson ImmunoResearch, West Grove, PA): 100,000 events were acquired using a CyAn ADP Flow Cytometer (DAKO Cytomation, Glostrup, Denmark) and analyzed with FlowJo software (Tree Star, Standford, CA, USA). /200 µL) were cultured for two days in serum-free X-vivo 10 medium (Lonza, Basel, Switzerland), 20% BIT9500 (Stem Cell Technologies, Vancouver, Canada) and growth factors. 12 Valproic acid (VA) was at 1 mM (Orfiril; Desitin, Liestal, Switzerland). Figure 2S and Table S1 ).
Purification and culture of AML and N-BM cells
Natural killer cell lines
Cellular cytotoxicity and colony-forming unit (CFU) assays
The cytotoxic activity of single KIR + NK cells against K562 erythroleukemia, and FACS-sorted AML PB, N-BM and N-mPB cell subpopulations was tested by chromium-release assay with 2-5×10 3 targets/well at indicated effector to target (E:T) ratios. 12 For blocking experiments, NK effectors were preincubated with anti-NKG2D mAb (M585; D. Cosman) or mouse IgG1k (BD Biosciences) at 10 mg/mL for one hour at 37°C. For CFU assays, FACSsorted AML (1×10 
CD38
-cells before (d0) and after two days exposure to medium alone (M) or VA; *p<0.05, statistical significance of NKG2D-L expression in response to VA, as compared to d0, and to M. tions were seeded into 1% methylcellulose, 17 either immediately or after 2-day culture in medium or with VA, and additional 4 h incubation without or with NK cells at E:T ratio of 5:1. Primary CFUs were counted after 14 days in an inverted microscope, harvested, and all cells were replated into secondary methylcellulose cultures.
Statistical analysis
Expression of NKG2D-L and cytolysis by NK cells were analyzed using Student's t test.
Results and Discussion
The AML-LSCs, defined phenotypically as the CD45 dim CD34 +
CD38
-population and analysed in de novo untreated AML, expressed low/undetectable levels of NKG2D-L, including UL-16 binding proteins (ULBP1-3) and MHC-related MICA/B molecules ( Figure 1A ). Ligands were also at background levels on N-BM CD34 +
-HSCs ( Figure 1B ). The paucity of NKG2D-L on AML-LSCs supports earlier findings with leukemic myeloblasts. 12 The absence of NKG2D receptor-dependent interactions is known to accelerate cancer progression, 18 and conversely, tumors which up-regulate cell surface NKG2D-L in response to cellular stress, DNA damage or pharmacological treatment are rendered susceptible to killing by NK cells. 19, 20 We have recently demonstrated that NKG2D-L levels increased in response to histone deacetylase (HDAC)-inhibitor VA, a drug with antineoplastic activities, and this increase enhanced the cytolysis of AML blasts. 12 Here, we observed a VA-dependent upregulation of NKG2D-L on CD34 +
-LSCs ( Figure  1C) , whereas no response to VA was seen with N-BM HSCs ( Figure 1D ). The VA effect on AML-LSCs was modest, but apparent with ULBP1 and MICA/B, the expression of which increased 2.0±0.8 and 1.9±1.5 fold, respectively (p<0.05; Figure 1E ).
To test whether AML-LSCs are susceptible to NK cellmediated lysis, NK effectors carrying single KIR specificities were selected according to patients' HLA class I allotypes (Online Supplementary Table S1 ). HLA-mismatched, but not HLA-matched, single KIR + NK cells were able to lyse purified AML-CD34 Table S1 . cells from individual patients (n=3, range 15-55% at E:T ratio of 10:1) but lysis was always seen using HLA-mismatched and not HLA-matched effectors, in accordance with our earlier studies on unfractionated leukemic blasts. 12 Single KIR + NK cells expressed also the inhibitory receptor NKG2A on 30-60% of cells, but NKG2A ligand HLA-E on AML targets was low or absent (MFI-R<10), in comparison with high levels of KIR ligands HLA-ABC (MFI-R 100-300). Unlike with AML targets, neither HLA-mismatched nor HLA-matched NK cells lysed purified N-BM CD34 + cells or N-mPB CD34 
-LSCs with VA resulted in an increase in susceptibility to alloreactive single KIR + NK cells which was consistently observed at 10:1 to 0.6:1 E:T ratios, but the extent of which varied dependent on AML targets ( Figure 2C ). This was likely linked to VA-mediated upregulation of cell-surface NKG2D-L ( Figure 1C ). The cytolysis of LSCs was indeed partly NKG2D-dependent, as it was specifically reduced in the presence of anti-NKG2D mAbs, the blocking effect of which was particularly pronounced with VA-treated AML cells ( Figure 2D ). To define the effect of NK cells on the colony-forming properties of LSCs, 21 serial replating CFU assays were performed and colony numbers generated from purified AML and N-BM subpopulations in response to VA and single-KIR + NK cells were monitored ( Figure 3A-C Table S1 . Results are shown as mean of duplicate analyses. Cultures in which no CFU-derived colonies were seen are indicated with "0".
A B C
used; in contrast to AML, HSC-derived colonies do not support serial replatings ( Figure 3C ). The 1 st CFU numbers from N-BM HSCs were unaffected by exposure to single-KIR + mismatched NK cells, and were preserved after VA treatment, 22 indicating that allorecognition by single KIR + NK cells is specific towards malignant colony-forming LSCs.
In this first report addressing the susceptibility of AML-LSCs to NK cells, we demonstrate that selection of NK effectors with a predicted KIR-HLA class I mismatch is prerequisite for targeting AML-LSCs. Allorecognition can be increased by VA which up-regulates NKG2D-L, thus priming the AML for the cytotoxic effectors and underlying the importance of interventions which enhance the NKG2D axis for tumor recognition. VAinduced epigenetic modifications may also promote the entry of LSCs into the cell cycle rendering them more accessible to chemo-and immunotherapies. 23 Importantly, we show that healthy CD34 +
CD38
-cells containing the HSCs are not targeted by HLA-mismatched NK cells and do not respond to VA, indicating that normal hematopoietic functions will be spared and arguing for the specificity in eradication of malignant CD34 + CD38 -cells containing the LSCs. Our data reinforce the concept of alloreactive NK cell-based adoptive immunotherapy, 24 in combination with antineoplastic drugs to enhance the tumor reactivity, as a rational strategy towards curing leukemia.
